Incyte Announces Positive Topline Results From Two Phase 3 Clinical Trials of Povorcitinib in Patients With Hidradenitis Suppurativa
Incyte (Nasdaq: INCY) today announced positive topline results from its pivotal Phase 3 STOP-HS clinical trial program evaluating the safety and efficacy of povorcitinib (INCB054707), an oral small-molecule JAK1 inhibitor, in adult patients (≥18 years) with moderate to severe hidradenitis suppurativa (HS).
Both the STOP-HS1 and STOP-HS2 studies met their primary endpoint at both tested doses (45 mg and 75 mg). A significantly higher proportion of patients treated with povorcitinib once daily (QD) versus placebo achieved Hidradenitis Suppurativa Clinical Response (HiSCR), a ≥50% reduction from baseline in the total abscess and inflammatory nodule count (AN count), with no increase from baseline in abscess or draining tunnel count. The percentage of povorcitinib treated patients achieving HiSCR50 compared to placebo at Week 12 was:
STOP-HS1: | 45 mg: 40.2% vs. 29.7% [P=0.024] 75 mg: 40.6% vs 29.7% [P=0.022] |
STOP-HS2: | 45 mg: 42.3% vs. 28.6% [P=0.004] 75 mg: 42.3% vs. 28.6% [P=0.003] |
Within a predefined subgroup of patients previously exposed to biologics, povorcitinib demonstrated greater differential efficacy (HiSCR50) when compared to placebo (nominal P-values):
STOP-HS1: | 45 mg: 34.2% vs. 21.9% [P=0.096] 75 mg: 37.8% vs. 21.9% [P=0.037] |
STOP-HS2: | 45 mg: 45.0% vs. 19.5% [P=0.001] 75 mg: 40.0% vs. 19.5% [P=0.005] |
In addition, at Week 12, patients treated with povorcitinib achieved deep levels of clinical response with a greater proportion achieving HiSCR75, reduction in flares, >3-point decrease in the Skin Pain Numeric Rating Scale (NRS) score and Skin Pain NRS30. Furthermore, povorcitinib demonstrated rapid onset of response, including rapid skin pain reduction.
The overall safety profile of povorcitinib is consistent with previous data. No new safety signals were observed and both doses were well tolerated.
"Hidradenitis suppurativa is a challenging and debilitating condition without a cure. Given the limitations of current HS treatments and its impact on patients’ daily lives, there is a critical need for new, well tolerated and effective therapies that provide a rapid reduction in the signs and symptoms of HS, in particular, pain," said Steven Stein, M.D., Chief Medical Officer, Incyte. "The positive Phase 3 data highlights the potential of povorcitinib as an effective oral treatment option for people living with HS.”
These data support the planned regulatory submission of povorcitinib for the treatment of HS worldwide. Additionally, data from both STOP-HS studies will be submitted for presentation at upcoming scientific meetings.
About STOP-HS
The STOP-HS clinical trial program includes two Phase 3 studies, STOP-HS1 (NCT05620823) and STOP-HS2 (NCT05620836), evaluating the efficacy and safety of povorcitinib (INCB54707) in adult patients with moderate to severe HS. Both studies include a 12-week double-blind, placebo-controlled treatment period, followed by a 42-week extension period and 30-day safety follow-up.
The studies have each enrolled approximately 600 patients (age ≥18 years) diagnosed with moderate to severe HS for at least three months prior to the screening visit and meet certain criteria: total AN count of ≥5, lesions in at least two distinct anatomical areas, and have a documented history of inadequate response to at least a three-month course of at least one conventional systemic therapy (oral antibiotic or biologic drug) for HS, or have demonstrated intolerance to, or have a contraindication to, such conventional systemic therapies.
The primary endpoint for both studies is the proportion of patients who achieve HiSCR50, defined as at least a 50% reduction from baseline in the total AN count at Week 12, with no increase from baseline in abscess or draining tunnel count. Key secondary endpoints include the proportion of patients achieving a 75% reduction in AN count with no increase from baseline in abscess or draining tunnel count (HiSCR75) at Week 12, the proportion of patients experiencing at least one flare-up over 12 weeks, the proportion of patients with a >3-point decrease in the Skin Pain NRS score among those with a baseline score of ≥3, and the proportion of patients achieving a 30% reduction and at least 1-unit reduction from baseline in Skin Pain NRS at Week 12. The studies also evaluate the frequency and severity of adverse events during the study.
For more information on the STOP HS studies, please visit https://clinicaltrials.gov/study/NCT05620823 and https://clinicaltrials.gov/study/NCT05620836.
Incyte Conference Call and Webcast
Incyte will hold a conference call and webcast today at 8:00 a.m. ET. To access the conference call, please dial 877-407-3042 for domestic callers or +1 201-389-0864 for international callers. When prompted, provide the conference identification number: 13752265. If you are unable to participate, a replay of the conference call will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1 201-612-7415. To access the replay, you will need the conference identification number: 13752265.
The conference call will also be webcast live and can be accessed at investor.incyte.com.
About Hidradenitis Suppurativa
Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses that can lead to irreversible tissue destruction and scarring.i,ii Over-activity of the JAK/STAT signaling pathway is believed to drive inflammation involved in the pathogenesis and progression of HS.iii More than 150,000 patients in the U.S. are estimated to have moderate to severe HS.iv Given the debilitating nature of the condition, it can have a profoundly negative effect on patients’ quality of life.v
About Povorcitinib
Povorcitinib (INCB54707) is an oral small-molecule JAK1 selective inhibitor currently in Phase 3 clinical trials for HS, vitiligo and prurigo nodularis (PN), as well as Phase 2 trials for asthma and chronic spontaneous urticaria (CSU).
Incyte Forward-Looking Statements
Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the regulatory submissions for povorcitinib worldwide; the submission of STOP-HS data for presentation at upcoming scientific meetings; the potential of povorcitinib to be an effective and well-tolerated treatment option for HS patients; and further clinical studies of povorcitinib, contain predictions, estimates and other forward-looking statements.
These forward-looking statements are based on Incyte’s current expectations and subject to risks and uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; determinations made by the FDA and other regulatory authorities; the efficacy or safety of Incyte’s products; the acceptance of Incyte’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in Incyte’s reports filed with the Securities and Exchange Commission, including its annual report for the year ended December 31, 2024. Incyte disclaims any intent or obligation to update these forward-looking statements.
1 | National Center for Advancing Translational Science Genetic and Rare Diseases Information Center. Hidradenitis suppurativa. https://rarediseases.info.nih.gov/diseases/6658/hidradenitis-suppurativa. Accessed February 7, 2024. |
2 | Kirby, JS et al. (2024). Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. Journal of the American Academy of Dermatology, Volume 90, Issue 3, 521-529. |
3 | Maronese, CA et al (2024). Biologics for Hidradenitis suppurativa: evolution of the treatment paradigm. Expert Review of Clinical Immunology, Volume 20, Issue 5, 525-545. |
4 | McMillan, K. Hidradenitis suppurativa: number of diagnosed patients, demographic characteristics, and treatment patterns in the United States. Am J Epidemiol. 2014 Jun 15;179(12):1477-83. doi: 10.1093/aje/kwu078. Epub 2014 May 8. |
5 | Sabat, R et al (2025). Hidradenitis suppurativa. The Lancet, Volume 405, Issue 10476, 420-438. |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317947508/en/
Contacts
Media
media@incyte.com
Investors
ir@incyte.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
LUMENION sets new standards with CO2-free process steam for industrial applications18.3.2025 11:00:00 EET | Press release
LUMENION has successfully completed the test operation of a plant for the supply of "green steam" in combination with a large-scale thermal storage solution. The completion of this LUMENION solution marks an important milestone on the way to a decarbonized industry. The TÜV-certified system is available for applications in all industrial sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318462006/en/ LUMENION TES LUMENION's thermal energy storage system uses a few hours of electricity supply to charge and to store energy in the form of heat of up to 600° Celsius. The energy can be charged flexibly at intervals throughout the day and is made available to customers in the form of steam or process heat over longer periods of time. Ideally, cheap electricity is obtained from the client's own renewable energy sources or during attractive time slots in the electricity market, which reduces the need for fossil fuels and al
Solidsoft Reply Successfully Integrates the Hellenic Medicines Verification System into the European Medicines Verification Platform18.3.2025 11:00:00 EET | Press release
In collaboration with the Hellenic Medicines Verification Organisation (HMVO), Solidsoft Reply, a Reply Group company specialising in Microsoft Azure cloud-based enterprise solutions, has successfully integrated Greece’s Hellenic Medicines Verification System (HMVS) within the European Hub, delivering the launch on schedule. This achievement enhances Greece’s pharmaceutical landscape and protects its citizens from the growing threat of falsified medications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318137690/en/ The HMVS now operates as part of the European Medicines Verification System (EMVS), a pan-national platform designed to prevent counterfeit medicines from entering the market and reaching patients. With this launch, Greece joins a growing network of 15 other fully operational and secure National Medicine Verification System (NMVS) platforms across Europe, powered by Solidsoft Reply. The HMVS became fully ope
Japan Sake and Shochu Makers Association: Global Beverage Experts Explore Japan’s Sake, Honkaku Shochu, and Awamori Culture18.3.2025 10:19:00 EET | Press release
The Japan Sake and Shochu Makers Association (JSS) is hosting a special tour inviting top professionals from the global wine and bar industries to explore the depth and heritage of Japan’s sake, honkaku shochu, and awamori culture. This exclusive program offers first-hand experience of Japan’s traditional brewing and distilling techniques, which were recently recognized as a UNESCO Intangible Cultural Heritage. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250316698311/en/ Leading Sommeliers Visiting a Rice Polishing Facility The sake tour brings together leading sommeliers and restaurant beverage directors from around the world to visit select breweries across Japan. Participants dive deep into the production process, learning about rice polishing, fermentation, and aging techniques unique to sake. The itinerary extends beyond brewery visits to an educational institute, offering specialized sessions on yeast selection, aro
Global Trust in Digital Services Declines, Finds Thales18.3.2025 10:00:00 EET | Press release
Thales, today announced the findings of its 2025 Digital Trust Index – Consumer Edition, revealing a universal decline in trust for digital services compared to this time last year. Across 13 different sectors, only insurance, banking and Government saw either their trust level remain unchanged or increase very slightly. When asked which sector they trusted with their personal data, not one sector reached above 50% approval. Thales surveyed over 14,000 consumers across 14 countries about their online relationship with brands and services, their privacy expectations, and how brands can earn their trust. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250318397240/en/ ©Thales This decline in trust comes as nearly one in five (19%) have been informed that their personal data has been compromised in the past year. Consequently, 82% have abandoned a brand in the past 12 months due to concerns about how their personal data was bein
Sofinnova Partners Exceeds Target With €165M Biotech Acceleration Fund, Europe’s Largest, With Strong Pharma Support18.3.2025 10:00:00 EET | Press release
Sofinnova Partners (“Sofinnova"), a leading European life sciences venture capital firm based in Paris, London, and Milan, today announced the final close of Sofinnova Biovelocita II. The fund has exceeded its target, successfully raising €165M, with substantial backing from the top global pharmaceutical companies, including Amgen, Bristol Myers Squibb, and Pfizer Ventures. This milestone marks a significant expansion of Sofinnova’s biotech acceleration strategy, extending beyond Italy to include France, the United Kingdom, and Denmark, with ambitions to further reach additional European countries in the future. Since its launch, the fund has screened over 300 projects and made several key investments into new companies across Europe driving cutting-edge innovation in biotechnology. Among the newly established companies are BioClec, focused on breakthrough therapies for Alzheimer’s disease; Forth Therapeutics, a spin-out of the University of Edinburgh, which is advancing next-generatio
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom